Alikiaii Babak, Majedi Mohammad Azad, Hashemi Seyed Taghi, Kiani Maryam
Department of Anesthesia and Critical Care, Anesthesiology and Critical Care Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Anesthesiology, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Adv Biomed Res. 2019 Feb 27;8:17. doi: 10.4103/abr.abr_165_18. eCollection 2019.
Constipation is an intestinal syndrome that can be created alone or in the context of another disease in patients admitted to intensive care units (ICUs). Given the role of sennosides in increasing the transfer rate of materials from the large intestine, we aimed to compare the effect of senalin with bisacodyl on the treatment of constipation in patients admitted to ICUs.
In this randomized, double-blind study, 70 patients admitted to the ICU were divided into two groups. The senalin recipient group received senalin with a dose of 500 mg daily for 3 days. The bisacodyl recipient group received bisacodyl with a dose of 10 mg daily for 3 days.
The mean of defecation frequency during the 2 day of treatment of constipation was significantly higher in the group receiving bisacodyl than in the senalin group ( < 0.01). There was no significant difference between the two groups in terms of fecal consistency in any of the study days ( < 0.05). The prevalence of complications in the 3 day of treatment was significantly higher in bisacodyl group than in the senalin group ( = 0.04).
Given the lack of difference in the efficacy of two drugs, fecal consistency, daily defecation frequency and fewer complications of senalin compared to bisacodyl, it s eems that this drug can be used as an appropriate treatment for constipation in patients admitted to ICUs.
便秘是一种肠道综合征,在重症监护病房(ICU)患者中,它可单独出现或与其他疾病并存。鉴于番泻苷在提高大肠物质转运率方面的作用,我们旨在比较塞奈林与比沙可啶对ICU住院患者便秘治疗的效果。
在这项随机、双盲研究中,70名入住ICU的患者被分为两组。塞奈林接受组每天服用500毫克塞奈林,共3天。比沙可啶接受组每天服用10毫克比沙可啶,共3天。
在便秘治疗的第2天,接受比沙可啶治疗组的排便频率均值显著高于塞奈林组(<0.01)。在任何研究日,两组在粪便稠度方面均无显著差异(<0.05)。在治疗的第3天,比沙可啶组的并发症发生率显著高于塞奈林组(=0.04)。
鉴于两种药物疗效无差异,与比沙可啶相比,塞奈林在粪便稠度、每日排便频率及并发症较少方面具有优势,似乎该药可作为ICU住院患者便秘的合适治疗药物。